The authors showed that agonists of α2-adrenergic receptors (α2-AR) had very strong anti-tumor activity when used as monotherapies in multiple immunocompetent tumor models, including immunecheckpoint blockade-resistant models, but not in immunodeficient models.
[Nature]
